Lipoprotein (a) measurements for clinical application
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and poses significant challenges to the development of immunoassays to measure its concentration in plasma or serum samples. Apo(a) is extremely variable in size not only between but also within individuals because of the presence of two different, genetically determined apo(a) isoform sizes. Therefore, the antigenic determinants per particle available to interact with the antibodies will vary in the samples and the calibrators, thus contributing to apo(a) size-dependent inaccuracy of different methods. The lack of rigorous validation of the immunoassays and common means of expressing Lp(a) concentrations hinder the harmonization of results obtained by different studies and contribute to the lack of common cut points for identification of individuals at risk for coronary artery disease or for interventions aimed at reducing Lp(a) levels. The aim of our review is to present and critically evaluate the issues surrounding the measurements of Lp(a), their impact on the clinical interpretation of the data, and the obstacles we need to overcome to achieve the standardization of Lp(a) measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels [88-90].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [90]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
Cited by
Items 301–337 of 337
郭, 明. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451650
Reiner, Ž., Miličić, D., Rogić, D., Manola, Š., Ružić, A., Canecki-Vražić, S., Kristić, I., Zulle, B.-L., Đerek, L., Šerić, V., et al. (2024) · Liječnički vjesnik · doi:10.26800/lv-146-1-2-7
Emerging Cardiovascular Risk Factors
Demeter, S. H., Papp, P., & Weidner, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_8
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2024-0090
“…riesgo cardiovascular por eleva-ción de Lp(a) altamente heterogénea y compleja, se decide asignar un valor objetivo en nmol/L de proteína Lp(a), teniendo en cuenta el polimor fi smo de tamaño de apo(a), que es el constituyente de la Lp(a) generalmente medido directa-mente por los inmunoensayos [48].”
Lipoproteina(a): fattore di rischio cardiovascolare tra clinica e laboratorio
Bonetti, G., & Carta, M. (2025) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.25.00279-8
The Process of Atheroma Growth, Vulnerability, and Rupture
Watanabe, T., & Fan, J. (2025) · Springer eBooks · doi:10.1007/978-981-96-3675-4_13
Familial Hypercholesterolemia in Women: Assessment, Diagnosis, and Treatment
Demeter, S. H., & Lew, K. (2025) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2505
Lipoprotein(a) prevalence trends in Portuguese children and adolescents: a real-world perspective
Ribeiro, I. M., Vieira, S., Saraiva, M., Tavares, M., Oliveira, J. C., Palma, I., & Mansilha, H. F. (2025) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.00339
Prognostic value of lipoprotein(a) in a primary prevention ambulatory cohort
Golan, N., Freund, O., Itach, T., & Arbel, Y. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02826-x
“Lp(a) levels were assessed using standardized immunochemical assays [19].”
Lipoprotein(a) and TAVR outcomes: Methodological challenges and clinical implications
Kalçık, M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.005
Zhang, Z., Zhao, L. Y., Wang, Z., Zhou, X., Li, X. X., Yang, W., & Xu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70491 · Cited by 1
“23,24,29 For categorical analyses, Lp(a) levels were divided into tertiles, with an additional category for the top 10% (1st – 33rd, 34th – 66th, 67th – 90th, and 91st – 100th percentiles).”
Lipoprotein(a) in acute coronary syndrome patients: A cross-sectional study
Thangjam, R. S., Singh, M. R., Singh, A. I., & Viksam, R. (2025) · Journal of Medical Society · doi:10.4103/jms.jms_60_25
Connolly, E., McLoughlin, S., O’Halloran, A. M., Hever, A. M., Nautiyal, K., McCormack, M., Crowley, V., & Kenny, R. A. (2026) · HRB Open Research · doi:10.12688/hrbopenres.14357.1
Kumaragiri, G., Sarup, S., Madhuri, M., Ali, A., Singh, A. M., Jagadesan, J., Kumari, B., Ahmed, S., Bhambhani, A., Hajela, K., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.101686
Apolipoprotein(a) inhibits hepatitis C virus through interaction with infectious particles
de Oliveira, C. G. (2016) · theses.fr (ABES) · doi:10.70675/7edc121bzc24dz4105za741z379a659aa834
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff · Cited by 1
Modani, S. M., Rampelly, S. K., Palagiri, S., Ibrahim, S. B., & Ramachandiran, S. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200657
“Angio-graphic investigations have reported that elevated Lp(a) correlates with a greater number of significantly stenosed vessels and higher Gensini or SYNTAX scores [66,69].”
Lu, Y., Jiang, D., Zhang, J., & Liang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s605053
The Genetic Stamp of Lipoprotein(a): Moving Beyond LDL for Cardiovascular Risk Estimation
Solimene, A., Luisi, E., Morello, M., Titolo, G., Serpico, C., Granata, M., Acampora, B., Bernazeaut, J., Loffredo, F. S., Golino, P., et al. (2026) · Targets · doi:10.3390/targets4030023
“This is because Lp(a) particles vary significantly in size due to differences in apo(a) isoforms, meaning that the same mass does not necessarily correspond to the same number of particles [56,57].”
Fahim, M., Eldawud, D., Wang, R., Gorantla, A., Khouri, P., Mitre, C. A., & Budzikowski, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.006
Reyes‐Soffer, G., & Ginsberg, H. N. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101111
“The availability of improved human plasma assays (5) enabled several groups to confirm the association be-tween Lp(a) concentrations and atherosclerotic cardiovascular (ASCVD) in large cohorts, while the cloning of the gene (6) and the identification of the importance of the number of LPA KIV2…”
Tsimikas, S., & Marcovina, S. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.027
Self-citationGencheva, I. I., & NUNEVA-DONCHEVA, R. (2026) · Diseases · doi:10.3390/diseases14080277
“The assay is independent of apo(a) isoform size, and its calibrator is traceable to the international reference material endorsed by IFCC [15,16].”
Granata, L. G., Giubilato, S., Campanella, F., Amico, F., Fusco, S. A. D., & Colivicchi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1886347 · Cited by 2
“This structural variability partly explains the marked interindividual variability in Lp(a) concentrations observed in the general population (25, 26).”
Sainz-Pastor, N., Anguila, S. C., Albéniz-Abaigar, M., Molina, A., Castella, H., Delgado, M., Bedini, J. L., Muñoz, R., Ortega, E., & Rico, N. (2026) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfag122
Gurbel, P. A., Tantry, U. S., Bliden, K. P., Ashley, W. W., Jeong, Y., & Tsimikas, S. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.324402
Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Carlson, A. M., Zayyad, Z. A., Driesenga, S., Boxley, P., Mishra, A., Uraizee, O., Ephrem, R., Zhang, R., Natsheh, Z., & Shroff, A. R. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00473-5
Gaps and disparities in Lp(a) testing before universal screening: A 10-year analysis
Patel, H. B., Bawahab, Y., & Vasile, V. C. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200701
“Results were reported in their original assay-specific units given the unreliability of conversions between mg/dL and nmol/L [21 – 23].”
Zadeh, S. S. T., Pang, J., Chan, D. C., Hillis, G. S., Schultz, C. J., Lan, N. S. R., Woodward, A.-M., Barnett, W., & Watts, G. F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.011 · Cited by 1
Lipoprotein(a) measurement: challenges and opportunities
Contois, J. H. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-1262
“Analytical methods based on the Denka reagent cannot be considered standardized and no claim should be made by the manufacturers or by the users on their independence from apo(a) size variability ” [25].”
Arca, M., Marcucci, R., Maggioni, A. P., Bilato, C., Stabile, E., Cipollone, F., Capodanno, D., Liuzzo, G., Varbella, F., Guerra, F., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1906713
“Indeed, multiple assay types remain in use, with values reported in mg/dL and nmol/L that are not directly interchangeable, leading to misestimation and limiting comparability across results (28, 36, 37).”
Gómez-Barrado, J. J., Turégano-Yedro, M., Cerpa, M. Á. S., Majluf, E. E., Ferrer, C. G., Campillos, R. C., García-Jambrina, M., Bermúdez, E. M., Garay, R. S. G., Soto, A. M., et al. (2026) · Cardiology · doi:10.1159/crd/absag011
Tan, S., Gu, J., Yow, D., & Zheng, L. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100913 · Cited by 1
“The use of both mg/dL and nmol/L further complicates interpretation because fixed conversion between mass and molar units is imprecise across apolipoprotein(a) isoform sizes [6].”
Lipoprotein(a) analytical variation and cardiovascular thresholds
Bargnoux, A., Aamoum, A., Grillet, P.-E., Plawecki, M., Dupuy, A., Roubille, F., & Cristol, J. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-1481
“A size polymorphism of the apo(a) (300 – 800 kDa) is caused by copy number variation (2 – 40 An overview of current data [9, 10] in measurement of Lp(a) highlighted the need for standardization of measurement methods and reporting unit for concentration (mg/dL or nmol/L).”
Cobbaert, C. M., Taranto, M. D. D., Fabre-Estremera, B., Lackner, K. J., Langlois, M. R., Özcan, O., & Pulkki, K. J. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-1363
Lipoprotein(a): Bridging the gap between risk prediction, measurement, and emerging therapeutics
Abbas, W., Kanwal, A., Mian, S., Syed, F. A., Rukh, S., Ahmad, H., Aijaz, M. S., Mudasir, M., Collins, S., Amin, S., et al. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200724
Metadata
- Authors
- Marcovina, S. M., & Albers, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- Marcovina, Santica M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 57
- Issue
- 4
- Pages
- 526-537
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4808779
- OpenAlex
- W2313206757
- Cited by
- 338
- References
- 49
- Citations by year
- 2026: 44 · 2025: 36 · 2024: 37 · 2023: 45 · 2022: 31 · 2021: 29 · 2020: 35 · 2019: 28 · 2018: 16 · 2017: 26 · 2016: 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1631 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), apolipoprotein(a), apo(a) isoforms, immunoassay standardization, antibody specificity, size heterogeneity, assay validation, measurement harmonization, coronary artery disease risk, clinical interpretation
- MeSH terms
- Apolipoproteins A, Cardiovascular Diseases, Data Interpretation, Statistical, Humans, Immunoassay, Reference Standards, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.